Radiolabeled annexin-V for monitoring treatment response in oncology.
Because of its potential to allow for noninvasive, repetitive, and selective in vivo identification of the site and extent of apoptotic cell death and for monitoring cell death kinetics without the need for invasive biopsy, radiolabeled annexin-V is of major clinical relevance. This paper reviews available preclinical and clinical data on radiolabeled annexin-V pertaining to the domain of monitoring response to radiotherapy and chemotherapy, focusing especially on advantages and drawbacks of the different labeling procedures for the radiolabeling of annexin-V.
Van de Wiele
Christophe
C
Department of Head and Neck Surgery, University Hospital Ghent, Ghent, Belgium. christophe.vandewiele@ugent.be
Vermeersch
Hubert
H
Loose
David
D
Signore
Alberto
A
Mertens
Nico
N
Dierckx
Rudi
R
D000818:Animals; D017304:Annexin A5 / Q000032:analysis*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007553:Isotope Labeling / Q000379:methods*; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*
D017304:Annexin A5